Survey on Recommended Health Care for Adult Patients with Myelodysplastic Syndromes Identifies Areas for Improvement.

Chanias, Ioannis; Wilk, C Matthias; Benz, Rudolf; Daskalakis, Michael; Stüssi, Georg; Schmidt, Adrian; Bacher, Ulrike; Bonadies, Nicolas (2020). Survey on Recommended Health Care for Adult Patients with Myelodysplastic Syndromes Identifies Areas for Improvement. International journal of environmental research and public health, 17(24) Molecular Diversity Preservation International MDPI 10.3390/ijerph17249562

ijerph-17-09562.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (328kB) | Preview

The impact on health care of patients with myelodysplastic syndromes (MDS) is continuously rising. To investigate the perception of hemato-oncologists concerning the recommended MDS patient care in Switzerland, we conducted a web-based survey on diagnosis, risk-stratification and treatment. 43/309 physicians (13.9%) replied to 135 questions that were based on current guidelines between 3/2017 and 2/2018. Only questions with feedback-rates >50% were further analysed and ratios >90% defined "high agreement", 70-90% "agreement", 30-70% "insufficient agreement" and <30% "disagreement". For diagnosis, we found insufficient agreement on using flow-cytometry, classifying MDS precursor conditions, performing treatment response assessment after hypomethylating agents (HMA) and evaluating patients with suspected germ-line predisposition. For risk-stratification, we identified agreement on using IPSS-R but insufficient agreement for IPSS and patient-based assessments. For treatment, we observed disagreement on performing primary infectious prophylaxis in neutropenia but agreement on using only darbepoetin alfa in anaemic, lower-risk MDS patients. For thrombopoietin receptor agonists, insufficient agreement was found for the indication, preferred agent and triggering platelet count. Insufficient agreement was also found for immunosuppressive treatment in hypoplastic MDS and HMA dose adjustments. In conclusion, we identified areas for improvement in MDS patient care, in need of further clinical trials, information, and guiding documents.

Item Type:

Journal Article (Original Article)


04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > Unit Childrens Hospital > Forschungsgruppe Hämatologie (Erwachsene)

UniBE Contributor:

Chanias, Ioannis; Daskalakis, Michael; Bacher, Vera Ulrike and Bonadies, Nicolas


600 Technology > 610 Medicine & health




Molecular Diversity Preservation International MDPI




Anja Ebeling

Date Deposited:

07 Jan 2021 15:48

Last Modified:

07 Jan 2021 15:57

Publisher DOI:


PubMed ID:


Uncontrolled Keywords:

areas for improvement guideline-adherence myelodysplastic syndromes survey




Actions (login required)

Edit item Edit item
Provide Feedback